Ask the Experts: Endoscopic Lumbar Fusion Luke J. Kim, MD Don Park, MD Javier Qo, MD

Ask the Experts: Endoscopic Lumbar Fusion Luke J. Kim, MD Don Park, MD Javier Qo, MD

Endoscopic Lumbar Fusion

Ask the Experts: Role and Timing of Surgery of Acute Central Cord Syndrome Michael G. Fehlings, MD Konstantinos Margetis, MD Yi Lu, MD

Ask the Experts: Role and Timing of Surgery of Acute Central Cord Syndrome Michael G. Fehlings, MD Konstantinos Margetis, MD Yi Lu, MD

Role and Timing of Surgery of Acute Central Cord Syndrome

Author Jason Friedrich, MD discusses his detailed article, "Update on Nonsurgical Management of Adult Degenerative Scoliosis" with moderator Tejas Shah, MD. Friedrich is a physiatrist at University of Colorado School of Medicine; Shah is a resident and physiatrist at Hospital of the University of Pennsylvania.

Author Jason Friedrich, MD discusses his detailed article, "Update on Nonsurgical Management of Adult Degenerative Scoliosis" with moderator Tejas Shah, MD. Friedrich is a physiatrist at University of Colorado School of Medicine; Shah is a resident and physiatrist at Hospital of the University of Pennsylvania.

Update on Nonsurgical Management of Adult Degenerative Scoliosis

Ask the Experts: Spinal Deformity in the Setting of Spinal Tumors Daniel M. Sciubba, MD Joseph H. Schwab, MD Larry Lo, MD

Ask the Experts: Spinal Deformity in the Setting of Spinal Tumors Daniel M. Sciubba, MD Joseph H. Schwab, MD Larry Lo, MD

Spinal Deformity in the Setting of Spinal Tumors

Ask the Experts: Outpatient Spine Surgery: Trending Pearls and Pitfalls Mark Mikhael, MDCary Templin, MDDeepak Reddy, MD

Ask the Experts: Outpatient Spine Surgery: Trending Pearls and Pitfalls Mark Mikhael, MD Cary Templin, MD Deepak Reddy, MD

Outpatient Spine Surgery: Trending Pearls and Pitfalls

Ask the Experts: Current updates and evidence for regenerative intradiscal treatment options Gene Tekmyster, DO Zorica Buser, PhD, MBA Ken Blank, PhD, MS, MHA

Ask the Experts: Current updates and evidence for regenerative intradiscal treatment options Gene Tekmyster, DO Zorica Buser, PhD, MBA Ken Blank, PhD, MS, MHA

Current updates and evidence for regenerative intradiscal treatment options

Ask the Experts: Reconstruction of the Anterior Column of the Spine Sigurd Berven, MD John Williams, MD Jonathan Schoeff, MD Izzy Lieberman, MD, FRCSC, MBA

Ask the Experts: Reconstruction of the Anterior Column of the Spine Sigurd Berven, MD John Williams, MD Jonathan Schoeff, MD Izzy Lieberman, MD, FRCSC, MBA

Reconstruction of the Anterior Column of the Spine

Ask the Experts: Updates to SMaX: Prevention of Wrong-Site Spinal Surgery &amp; Procedures Gene Tekmyster, DO Addisu Mesfin, MD

Ask the Experts: Updates to SMaX: Prevention of Wrong-Site Spinal Surgery &amp; Procedures Gene Tekmyster, DO Addisu Mesfin, MD

Updates to SMaX: Prevention of Wrong-Site Spinal Surgery & Procedures

Ask the Experts: Role of Osteoporosis &amp; Spinal Deformity Tony Tannoury, MD Zeeshan Sardar, MD

Ask the Experts: Role of Osteoporosis &amp; Spinal Deformity Tony Tannoury, MD Zeeshan Sardar, MD

Role of Osteoporosis & Spinal Deformity

Author Manish K. Kasliwal, MD, MCh, FAANS, a neurosurgeon at University Hospitals Cleveland Medical Center, discusses his recent article, "Preoperative Optimization in Spine Surgery - A Review," with moderator Douglas Pahl, MD. 

Author Manish K. Kasliwal, MD, MCh, FAANS, a neurosurgeon at University Hospitals Cleveland Medical Center, discusses his recent article, "Preoperative Optimization in Spine Surgery - A Review," with moderator Douglas Pahl, MD.

Preoperative Optimization in Spine Surgery: A Review

The NASS Podcast is a great way to consume education content on-the-go! The episodes offer in-depth discussions of a variety of topics in spine from key opinion leaders, including: 3D Printing; ACDF vs. Cervical Disc Replacement; Complications; Laminoplasty vs. ACDF; Neuromonitoring During Spine Surgery; Cellular-Based Allografts; Is Surgery for Axial Back Pain Still an Option?; Surgical Management of Degenerative Spondylolisthesis; SpineLine Author Discussions.

The NASS Podcast is a great way to consume education content on-the-go! The episodes offer in-depth discussions of a variety of topics in spine from key opinion leaders, including: 3D Printing; ACDF vs. Cervical Disc Replacement; Complications; Laminoplasty vs. ACDF; Neuromonitoring During Spine Surgery; Cellular-Based Allografts; Is Surgery for Axial Back Pain Still an Option?; Surgical Management of Degenerative Spondylolisthesis; SpineLine Author Discussions.

The NASS Podcast

Faisel Zaman, MD, Chair of the Patient Education Committee, discusses causes and treatments for degenerative disc disease.  Disclosure: Zaman, Faisel M.: Nothing to Disclose  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Faisel Zaman, MD, Chair of the Patient Education Committee, discusses causes and treatments for degenerative disc disease. Disclosure: Zaman, Faisel M.: Nothing to Disclose Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Degenerative Disc Disease for Patients

Scott L. Blumenthal, MD, Rolando Garcia Jr., MD, MPH and Gregory D. Schroeder, MD debate anterior versus posterior cervical myelopathy.  Disclosures: Blumenthal, Scott L.: Royalties: Aesculap (A); Stock Ownership: FzioMed (less than 1%), VertiFlex (less than 1%), Centinel Spine (less than 1%); Consulting: Sites Medical (None), Aesculap (C), Vertera (None), Bayliss Medical (C), Orthofix (None); Speaking and/or Teaching Arrangements: Aesculap (D), VertiFlex (B), Bayliss (None); Scientific Advisory Board: Aesculap (B), FzioMed (None), VertiFlex (B). Garcia, Rolando: Consulting: Aesculap Implant Systems (C),  Centinel Spine (A); Device or Biologic Distribution Group (Physician-Owned Distributorship): Aesculap (C); Scientific Advisory Board: Aesculap Implant System (B); Speaking and/or Teaching Arrangements: Aesculap Implant Systems (Travel Expense Reimbursement); Trips/Travel: Aesculap Implant Systems (Travel Expense Reimbursement). Schroeder, Gregory Douglas: Board of Directors: CSRS, Clinical Spine Surgery (Nonfinancial); Consulting: Zimmer (C), Stryker (C), Advanced Medical (C), Medtronic (C); Trips/Travel: Aospine (C).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Scott L. Blumenthal, MD, Rolando Garcia Jr., MD, MPH and Gregory D. Schroeder, MD debate anterior versus posterior cervical myelopathy. Disclosures: Blumenthal, Scott L.: Royalties: Aesculap (A); Stock Ownership: FzioMed (less than 1%), VertiFlex (less than 1%), Centinel Spine (less than 1%); Consulting: Sites Medical (None), Aesculap (C), Vertera (None), Bayliss Medical (C), Orthofix (None); Speaking and/or Teaching Arrangements: Aesculap (D), VertiFlex (B), Bayliss (None); Scientific Advisory Board: Aesculap (B), FzioMed (None), VertiFlex (B). Garcia, Rolando: Consulting: Aesculap Implant Systems (C),  Centinel Spine (A); Device or Biologic Distribution Group (Physician-Owned Distributorship): Aesculap (C); Scientific Advisory Board: Aesculap Implant System (B); Speaking and/or Teaching Arrangements: Aesculap Implant Systems (Travel Expense Reimbursement); Trips/Travel: Aesculap Implant Systems (Travel Expense Reimbursement). Schroeder, Gregory Douglas: Board of Directors: CSRS, Clinical Spine Surgery (Nonfinancial); Consulting: Zimmer (C), Stryker (C), Advanced Medical (C), Medtronic (C); Trips/Travel: Aospine (C). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Cervical Myelopathy Anterior vs. Posterior

Featuring: Michael Y. Wang, MD, Michael P. Steinmetz, MD  Disclosures: Steinmetz, Michael P.: Royalties: Biomet Spine (B); Consulting: Intellirod (A), Stryker Spine (B), Globus (B); Speaking and/or Teaching Arrangements: Stryker (B); Board of Directors: AANS/CNS Section on Disorders of the Spine (Chair Exhibits Committee), Council of State Neurosurgical Societies (Vice Chair); Scientific Advisory Board: Intellirod (B). Wang, Michael Y.: Royalties: DePuy Synthes Spine (F); Stock Ownership: ISD (less than 1%), Medical Device Partners (less than 1%); Consulting: Stryker (C), Spineology (C), K2M (C), DePuy Synthes (C); Scientific Advisory Board: Vallum (A).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Michael Y. Wang, MD, Michael P. Steinmetz, MD Disclosures: Steinmetz, Michael P.: Royalties: Biomet Spine (B); Consulting: Intellirod (A), Stryker Spine (B), Globus (B); Speaking and/or Teaching Arrangements: Stryker (B); Board of Directors: AANS/CNS Section on Disorders of the Spine (Chair Exhibits Committee), Council of State Neurosurgical Societies (Vice Chair); Scientific Advisory Board: Intellirod (B). Wang, Michael Y.: Royalties: DePuy Synthes Spine (F); Stock Ownership: ISD (less than 1%), Medical Device Partners (less than 1%); Consulting: Stryker (C), Spineology (C), K2M (C), DePuy Synthes (C); Scientific Advisory Board: Vallum (A). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Robotics in Spine Surgery

Featuring: Zorica Buser, PhD, Mark Erwin, DC, PhD  Disclosures: Buser, Zorica: Consulting: AOSpine (B), Xenco Medical (B); Research Support (Investigator Salary): SeaSpine (F, Paid directly to institution/employer); Research Support (Staff and/or materials): SeaSpine (F, Paid directly to institution/employer); Trips/Travel: AOSpine (Travel Expense Reimbursement). Erwin, William Mark: Board of Directors: Notogen (Stock Ownership disclosed); Grants: Skoll Family Trust (G,Paid directly to institution/employer); Research Support (Investigator Salary): Canadian Chiropractic Research Foundation (D); Research Support (Staff and/or materials): Skoll Family Trust (F, Paid directly to institution/employer); Scientific Advisory Board: Notogen (Stock Ownership dislcosed); Stock Ownership (including options, warrants): Notogen Inc (33%).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Zorica Buser, PhD, Mark Erwin, DC, PhD Disclosures: Buser, Zorica: Consulting: AOSpine (B), Xenco Medical (B); Research Support (Investigator Salary): SeaSpine (F, Paid directly to institution/employer); Research Support (Staff and/or materials): SeaSpine (F, Paid directly to institution/employer); Trips/Travel: AOSpine (Travel Expense Reimbursement). Erwin, William Mark: Board of Directors: Notogen (Stock Ownership disclosed); Grants: Skoll Family Trust (G,Paid directly to institution/employer); Research Support (Investigator Salary): Canadian Chiropractic Research Foundation (D); Research Support (Staff and/or materials): Skoll Family Trust (F, Paid directly to institution/employer); Scientific Advisory Board: Notogen (Stock Ownership dislcosed); Stock Ownership (including options, warrants): Notogen Inc (33%). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Injectable Biologic Therapies for Intervertebral Disc

Featuring: Scott Blumenthal, MD, Richard D. Guyer, MD, Jack E. Zigler, MD  Disclosures: Blumenthal, Scott: Royalties: Aesculap (A); Stock Ownership: FzioMed (1%), VertiFlex (1%), Centinel Spine (1%); Consulting: Sites Medical (None), Aesculap (C), Vertera (None), Bayliss Medical (C), Orthofix (None); Speaking and/or Teaching Arrangements: Aesculap (D), VertiFlex (B), Bayliss (None); Scientific Advisory Board: Aesculap (B), FzioMed (None), VertiFlex (B).  Guyer, Richard D.: Royalties: Alphatec (B); Stock Ownership: Spinal Motion (None); Private Investments: Spinal Ventures I and II (5%); Consulting: DePuy/Synthes (B); Speaking and/or Teaching Arrangements: Synthes (None); Scientific Advisory Board: K2M (B), Spinal Kinetics (Stock options), Nanovis (Stock options), Crocker Technologies (None), MiMedx (None); Fellowship Support: NuVasive (D, Paid directly to institution/employer).  Zigler, Jack E.: Consulting: Aesculap (C), Centinel Spine (C), FloSpine (B), Medtronic Spine (B), Orthofix (B), Simplify Medical (B); Royalties: Zimmer Spine (B); Scientific Advisory Board: Safe Orthopedics (Future Compensation Expected).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Scott Blumenthal, MD, Richard D. Guyer, MD, Jack E. Zigler, MD Disclosures: Blumenthal, Scott: Royalties: Aesculap (A); Stock Ownership: FzioMed (1%), VertiFlex (1%), Centinel Spine (1%); Consulting: Sites Medical (None), Aesculap (C), Vertera (None), Bayliss Medical (C), Orthofix (None); Speaking and/or Teaching Arrangements: Aesculap (D), VertiFlex (B), Bayliss (None); Scientific Advisory Board: Aesculap (B), FzioMed (None), VertiFlex (B).  Guyer, Richard D.: Royalties: Alphatec (B); Stock Ownership: Spinal Motion (None); Private Investments: Spinal Ventures I and II (5%); Consulting: DePuy/Synthes (B); Speaking and/or Teaching Arrangements: Synthes (None); Scientific Advisory Board: K2M (B), Spinal Kinetics (Stock options), Nanovis (Stock options), Crocker Technologies (None), MiMedx (None); Fellowship Support: NuVasive (D, Paid directly to institution/employer).  Zigler, Jack E.: Consulting: Aesculap (C), Centinel Spine (C), FloSpine (B), Medtronic Spine (B), Orthofix (B), Simplify Medical (B); Royalties: Zimmer Spine (B); Scientific Advisory Board: Safe Orthopedics (Future Compensation Expected). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Cervical Disc Replacement

Jeffrey C. Wang, MD (University of Southern California Spine Center), Raymond J. Hah, MD (Keck School of Medicine at University of Southern California), John C. France, MD (West Virginia University) and Sheeraz A. Qureshi, MD, MBA (Mount Sinai School of Medicine) discuss laminoplasty vs. anterior cervical fusion.  Disclosures: France, John C.: Nothing to Disclose   Hah, Raymond J: Consulting: Nuvasive (D). Qureshi, Sheeraz A: Board of Directors: Minimally Invasive Spine Surgery Group (Nonfinancial); Consulting: Globus (B),  K2M (D), Paradigm Spine (C), RTI (Nonfinancial), Stryker Spine (D); Other: Healthgrades (B); Other Office: AAOS (Nonfinancial, Evaluations Committee member), CSRS (Nonfinancial, Program Committee), CSRS (Nonfinancial, Survey Committee), NASS (Nonfinancial, MIS Committee), NASS (Nonfinancial, Value Committee); Private Investments (including venture capital, start-ups): Avaz Surgical (2%), Vital 5 (2%); Scientific Advisory Board: Onpoint Surgical, Inc. (Nonfinancial), Zimmer (Nonfinancial); Speaking and/or Teaching Arrangements: Globus (Nonfinancial), Medtronic (Nonfinancial), Stryker (Nonfinancial). Wang, Jeffrey C.: Board of Directors: AOFoundation (C), Cervical Spine Research Society (Travel Expenses), North American Spine Society (Travel Expenses); Fellowship Support: AO Foundation (E, Paid directly to institution/employer); Private Investments: Bone Biologics (less than 1%), electrocore (less than 1%), pearldiver (less than 1%), surgitech (less than 1%); Royalties: Amedica (B), Biomet (F), DePuy Synthes (C), SeaSpine (C).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Jeffrey C. Wang, MD (University of Southern California Spine Center), Raymond J. Hah, MD (Keck School of Medicine at University of Southern California), John C. France, MD (West Virginia University) and Sheeraz A. Qureshi, MD, MBA (Mount Sinai School of Medicine) discuss laminoplasty vs. anterior cervical fusion. Disclosures: France, John C.: Nothing to Disclose   Hah, Raymond J: Consulting: Nuvasive (D). Qureshi, Sheeraz A: Board of Directors: Minimally Invasive Spine Surgery Group (Nonfinancial); Consulting: Globus (B),  K2M (D), Paradigm Spine (C), RTI (Nonfinancial), Stryker Spine (D); Other: Healthgrades (B); Other Office: AAOS (Nonfinancial, Evaluations Committee member), CSRS (Nonfinancial, Program Committee), CSRS (Nonfinancial, Survey Committee), NASS (Nonfinancial, MIS Committee), NASS (Nonfinancial, Value Committee); Private Investments (including venture capital, start-ups): Avaz Surgical (2%), Vital 5 (2%); Scientific Advisory Board: Onpoint Surgical, Inc. (Nonfinancial), Zimmer (Nonfinancial); Speaking and/or Teaching Arrangements: Globus (Nonfinancial), Medtronic (Nonfinancial), Stryker (Nonfinancial). Wang, Jeffrey C.: Board of Directors: AOFoundation (C), Cervical Spine Research Society (Travel Expenses), North American Spine Society (Travel Expenses); Fellowship Support: AO Foundation (E, Paid directly to institution/employer); Private Investments: Bone Biologics (less than 1%), electrocore (less than 1%), pearldiver (less than 1%), surgitech (less than 1%); Royalties: Amedica (B), Biomet (F), DePuy Synthes (C), SeaSpine (C). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Laminoplasty vs. ACDF

Featuring: Joseph S. Butler, PhD, FRCS, Gregory D. Schroeder, MD  Disclosures: Butler, Joseph S.: Nothing to Disclose   Schroeder, Gregory Douglas: Board of Directors: CSRS, Clinical Spine Surgery (Nonfinancial); Consulting: Zimmer (C), Stryker (C), Advanced Medical (C), Medtronic (C); Trips/Travel: Aospine (C).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Joseph S. Butler, PhD, FRCS, Gregory D. Schroeder, MD Disclosures: Butler, Joseph S.: Nothing to Disclose   Schroeder, Gregory Douglas: Board of Directors: CSRS, Clinical Spine Surgery (Nonfinancial); Consulting: Zimmer (C), Stryker (C), Advanced Medical (C), Medtronic (C); Trips/Travel: Aospine (C). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Trends in Decision Making for Biologics

[10 of 12]  Section on Intraoperative Neurophysiological Monitoring (IONM) Section Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss, "Diagnostic accuracy of IONM from the neurophysiologist’s perspective." They review the traditional diagnostic table (i.e., ± alert, ± deficit) and consider other factors like intervention, resolution of data, type of monitoring modality, etc. They also present an advanced diagnostic table that is inclusive of these factors. This has major implications for developing and interpreting research.  Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

[10 of 12] Section on Intraoperative Neurophysiological Monitoring (IONM) Section Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss, "Diagnostic accuracy of IONM from the neurophysiologist’s perspective." They review the traditional diagnostic table (i.e., ± alert, ± deficit) and consider other factors like intervention, resolution of data, type of monitoring modality, etc. They also present an advanced diagnostic table that is inclusive of these factors. This has major implications for developing and interpreting research. Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Section on IONM: How to Optimize Neuromonitoring Episode 10

[6 of 12]  Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “How can you use neuromonitoring to guide and optimize positioning for spine surgery?” The patient is finally in position and neuromonitoring can’t get baselines. What do you do? If you elect to intervene, it’s a long process to retest baselines in a neutral position. Then, you have to reposition all over again. Here the Co-Chairs present a fast, efficient, systematic way to position a patient for any spine surgery to ensure the spinal cord is stable, and all peripheral nerves and plexi are not compressed or stretched. Also, they talk about positioning possibilities for all patients; not just those with unstable spines.   Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

[6 of 12] Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “How can you use neuromonitoring to guide and optimize positioning for spine surgery?” The patient is finally in position and neuromonitoring can’t get baselines. What do you do? If you elect to intervene, it’s a long process to retest baselines in a neutral position. Then, you have to reposition all over again. Here the Co-Chairs present a fast, efficient, systematic way to position a patient for any spine surgery to ensure the spinal cord is stable, and all peripheral nerves and plexi are not compressed or stretched. Also, they talk about positioning possibilities for all patients; not just those with unstable spines. Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Section on IONM: How to Optimize Neuromonitoring Episode 6

Featuring: F. Todd Wetzel, MD, John Ney, MD, Tara Stewart, PhD, DABNM  Disclosures: Wetzel, F. Todd: Stock Ownership: Relievant Medical (1%).  Ney, John: Board of Directors: American Society for Neuromonitoring (None); Consulting: Ceribell (B), SpecialtyCare (B); Other Office: American Academy of Neurology, Medical Economics and Management Committee (Travel Expense Reimbursement); Speaking and/or Teaching Arrangements: SpecialtyCare (Travel Expense Reimbursement).  Stewart, Tara: Private Investments: IONM Life LLC (Future Compensation Expected, Paid directly to institution/employer)  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: F. Todd Wetzel, MD, John Ney, MD, Tara Stewart, PhD, DABNM Disclosures: Wetzel, F. Todd: Stock Ownership: Relievant Medical (1%).  Ney, John: Board of Directors: American Society for Neuromonitoring (None); Consulting: Ceribell (B), SpecialtyCare (B); Other Office: American Academy of Neurology, Medical Economics and Management Committee (Travel Expense Reimbursement); Speaking and/or Teaching Arrangements: SpecialtyCare (Travel Expense Reimbursement).  Stewart, Tara: Private Investments: IONM Life LLC (Future Compensation Expected, Paid directly to institution/employer) Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Value-Based Gap Analysis of Neuromonitoring

[1 of 12] Hear Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “What information is critical to communicate to the IONM team and how far in advance of surgery?” It’s not uncommon for the IONM team to learn the details of the surgical procedure after incision, as it unfolds. This poses a number of problems. The IONM team needs to know detailed surgical plan, diagnosis and patient insurance information at least 48-hours in advance for non-emergent surgery. This will make IONM less likely to fail because the IONM team can make sure the correct equipment/electrodes/people are in the room, and the correct tests are being run with optimized anesthesia. This will also limit common issues with insurance.   Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

[1 of 12] Hear Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “What information is critical to communicate to the IONM team and how far in advance of surgery?” It’s not uncommon for the IONM team to learn the details of the surgical procedure after incision, as it unfolds. This poses a number of problems. The IONM team needs to know detailed surgical plan, diagnosis and patient insurance information at least 48-hours in advance for non-emergent surgery. This will make IONM less likely to fail because the IONM team can make sure the correct equipment/electrodes/people are in the room, and the correct tests are being run with optimized anesthesia. This will also limit common issues with insurance.  Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Section on IONM: How to Optimize Neuromonitoring Episode 1

Featuring: Mark M. Mikhael, MD, Christopher F. Wolf, MD, Nick Shamie, MD, Lisa A. Ferrara, PhD  Disclosures: Ferrara, Lisa A.: Consulting: OrthoKinetic Technologies (Salary, Paid directly to institution/employer); Scientific Advisory Board: 4Web (less than 1%), Diamond Orthopedics (Salary, Paid directly to institution/employer). Mikhael, Mark M.: Consulting: Clariance Spine (B), GS Medical (B). Shamie, Nick: Nothing to Disclose Wolf, Christopher F.: Nothing to Disclose  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Mark M. Mikhael, MD, Christopher F. Wolf, MD, Nick Shamie, MD, Lisa A. Ferrara, PhD Disclosures: Ferrara, Lisa A.: Consulting: OrthoKinetic Technologies (Salary, Paid directly to institution/employer); Scientific Advisory Board: 4Web (less than 1%), Diamond Orthopedics (Salary, Paid directly to institution/employer). Mikhael, Mark M.: Consulting: Clariance Spine (B), GS Medical (B). Shamie, Nick: Nothing to Disclose Wolf, Christopher F.: Nothing to Disclose Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Cervical Disc Arthroplasty - Surgeon Reluctance To Adopt The Technology

Featuring: Nathaniel P. Brooks, MD, Khoi D. Than, MD, Michael P. Steinmetz, MD  Disclosures: Brooks, Nathaniel P.: Other: NASS (Minimally Invasive Procedure Section Chair). Than, Khoi Duc: Consulting: Bioventus (B), Medtronic (A). Steinmetz, Michael P.: Royalties: Biomet Spine (B); Consulting: Intellirod (A), Stryker Spine (B), Globus (B); Speaking and/or Teaching Arrangements: Stryker (B); Board of Directors: AANS/CNS Section on Disorders of the Spine (Chair Exhibits Committee), Council of State Neurosurgical Societies (Vice Chair); Scientific Advisory Board: Intellirod (B).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Nathaniel P. Brooks, MD, Khoi D. Than, MD, Michael P. Steinmetz, MD Disclosures: Brooks, Nathaniel P.: Other: NASS (Minimally Invasive Procedure Section Chair). Than, Khoi Duc: Consulting: Bioventus (B), Medtronic (A). Steinmetz, Michael P.: Royalties: Biomet Spine (B); Consulting: Intellirod (A), Stryker Spine (B), Globus (B); Speaking and/or Teaching Arrangements: Stryker (B); Board of Directors: AANS/CNS Section on Disorders of the Spine (Chair Exhibits Committee), Council of State Neurosurgical Societies (Vice Chair); Scientific Advisory Board: Intellirod (B). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Treatment Options for L4-5 Mobile Degenerative Lumbar Spondylolisthesis: Open or MI

[3 of 12] Hear Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “Why does IONM need access to my patients and their charts before and after surgery?”  It’s not uncommon for hospitals/surgeons to prohibit the IONM team from interfacing with the patient before surgery. In addition to needing informed consent, the team needs to assess the patient’s neuro status and history to interpret the IONM data. Imaging/charts help to develop an appropriate IONM plan. Facesheets are essential to reimbursement. When the IONM team is unable to access patient records, they are monitoring in the dark (and for free).  Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

[3 of 12] Hear Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, “Why does IONM need access to my patients and their charts before and after surgery?” It’s not uncommon for hospitals/surgeons to prohibit the IONM team from interfacing with the patient before surgery. In addition to needing informed consent, the team needs to assess the patient’s neuro status and history to interpret the IONM data. Imaging/charts help to develop an appropriate IONM plan. Facesheets are essential to reimbursement. When the IONM team is unable to access patient records, they are monitoring in the dark (and for free). Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Section on IONM: How to Optimize Neuromonitoring Episode 3

[2 of 12] Hear from Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, "Neuromonitoring in spine surgery, can't anyone cover the case?" Did you know IONM is learned through on-the-job training, licensure does not exist, and certifications are not required for the technologist in your OR? After initial training, technologists can monitor very basic cases (e.g., PLIF), but they should spend years in training to learn more complex procedures (deformity, tumors). If a surgery isn’t booked accurately, the surgeon might get a very junior person assigned to a very complex case. Here we inform the listener of common practices around determining “competency” for performing IONM in spine surgery.   Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

[2 of 12] Hear from Section on Intraoperative Neurophysiological Monitoring (IONM) Co-Chairs Dr. Rich Vogel and Dr. Adam Doan discuss the question, "Neuromonitoring in spine surgery, can't anyone cover the case?" Did you know IONM is learned through on-the-job training, licensure does not exist, and certifications are not required for the technologist in your OR? After initial training, technologists can monitor very basic cases (e.g., PLIF), but they should spend years in training to learn more complex procedures (deformity, tumors). If a surgery isn’t booked accurately, the surgeon might get a very junior person assigned to a very complex case. Here we inform the listener of common practices around determining “competency” for performing IONM in spine surgery.  Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Section on IONM: How to Optimize Neuromonitoring Episode 2

Featuring: Paul R. Gause, MD, Sandeep N. Gidvani, MD   Disclosures: Gause, Paul R.: Speaking and/or Teaching Arrangements: Medtronic (C). Gidvani, Sandeep N.: Consulting: Xenco Medical  (B), Seaspine  (None), Spinal Balance  (None), SI Bone (None), Nuvasive (None).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Paul R. Gause, MD, Sandeep N. Gidvani, MD  Disclosures: Gause, Paul R.: Speaking and/or Teaching Arrangements: Medtronic (C). Gidvani, Sandeep N.: Consulting: Xenco Medical  (B), Seaspine  (None), Spinal Balance  (None), SI Bone (None), Nuvasive (None). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Ideal Treatment For a Symptomatic Grade I/II L4-5 Spondylolisthesis

Brandon Lawrence, MD (University of Utah) and Harvey E. Smith, MD (University of Pennsylvania Department of Orthopaedic Surgery) discuss cellular-based allografts.  Disclosures: Lawrence, Brandon Douglas: Board of Directors: AO Spine North America (Nonfinancial, Paid directly to institution/employer),  Cervical Spine Research Society (Nonfinancial, Paid directly to institution/employer); Fellowship Support: AO Spine North America (E, Paid directly to institution/employer); Trips/Travel: AO Spine North America (B, Paid directly to institution/employer). Smith, Harvey E.: Stock Ownership: Johnson And Johnson (200 Shares, 100.00%); Trips/Travel: Biedermann Medtech (A), Depuy/Johnson&amp;Johnson (A), Nuvasive (Nonfinancial), Stryker (A).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Brandon Lawrence, MD (University of Utah) and Harvey E. Smith, MD (University of Pennsylvania Department of Orthopaedic Surgery) discuss cellular-based allografts. Disclosures: Lawrence, Brandon Douglas: Board of Directors: AO Spine North America (Nonfinancial, Paid directly to institution/employer),  Cervical Spine Research Society (Nonfinancial, Paid directly to institution/employer); Fellowship Support: AO Spine North America (E, Paid directly to institution/employer); Trips/Travel: AO Spine North America (B, Paid directly to institution/employer). Smith, Harvey E.: Stock Ownership: Johnson And Johnson (200 Shares, 100.00%); Trips/Travel: Biedermann Medtech (A), Depuy/Johnson&amp;Johnson (A), Nuvasive (Nonfinancial), Stryker (A). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Cellular-Based Allografts

Featuring: Richard Vogel, PhD, DABNM, Adam Doan, DC, DABNM, Anthony K. Sestokas, PhD, DABNM   Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Sestokas, Anthony K.: Other Office: Journal Of Clinical Monitoring And Computing (Editorial board), NASS Section On Intraoperative Neuromonitoring (Member of Section on IONM), SpecialtyCare (F, Chief Clinical Officer - IONM; Salary); Stock Ownership: KSPC Holdings (C) Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Featuring: Richard Vogel, PhD, DABNM, Adam Doan, DC, DABNM, Anthony K. Sestokas, PhD, DABNM  Disclosures: Doan, Adam: Private Investments (including venture capital, start-ups): Veridical RCM, LLC (D). Sestokas, Anthony K.: Other Office: Journal Of Clinical Monitoring And Computing (Editorial board), NASS Section On Intraoperative Neuromonitoring (Member of Section on IONM), SpecialtyCare (F, Chief Clinical Officer - IONM; Salary); Stock Ownership: KSPC Holdings (C) Vogel, Richard: Board of Directors: American Board Of Neurophysiologic Monitoring (Nonfinancial, Examiner for Board), American Society Of Neurophysiological Monitoring (Nonfinancial, President of the Society (2019-2020)); Consulting: Medicolegal Expert Witness Consulting (D); Other: NuVasive (Salary); Speaking and/or Teaching Arrangements: Neurophysiology Services Australia (None); Trips/Travel: North American Spine Society (Travel Expense Reimbursement), University Of Sydney (Travel Expense Reimbursement). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

What Are The Real Criteria for a Neuromonitoring Alert In Spine Surgery?

Dr. Vivek Mohan discusses Lumbar Spine Fusion with one of his former patients.  Disclosure: Mohan, Vivek: Consulting: AIM Specialty Health (B), Baxter (B), Seaspine (C); Speaking and/or Teaching Arrangements: Providence Medical (B).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Dr. Vivek Mohan discusses Lumbar Spine Fusion with one of his former patients. Disclosure: Mohan, Vivek: Consulting: AIM Specialty Health (B), Baxter (B), Seaspine (C); Speaking and/or Teaching Arrangements: Providence Medical (B). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Lumbar Spine Fusion: The Patient's Perspective

Alexander R. Vaccaro, MD, PhD (Thomas Jefferson University), Rick C. Sasso, MD (Indiana Spine Group and Indiana University School of Medicine), Carlo Bellabarba, MD (University of Washington and Harborview Medical Center) and Christopher K. Kepler, MD, MBA (Thomas Jefferson University) discuss type II odontoid fractures.  Disclosures: Bellabarba, Carlo: Nothing to Disclose   Kepler, Christopher K.: Grants: NIH (I, Paid directly to institution/employer); Other Office: Clinical Spine Surgery (Nonfinancial); Research Support (Staff and/or materials): CSRS (D, Paid directly to institution/employer), RTI (C, Paid directly to institution/employer); Royalties: Inion (None). Sasso, Rick C.: Board of Directors: Cervical Spine Research Society (None); Consulting: NuVasive (C); Research Support (Staff and/or materials): Cerapedics (E, Paid directly to institution/employer), Medtronic (B, Paid directly to institution/employer), Smith and Nephew (D, Paid directly to institution/employer); Royalties: Medtronic (I). Vaccaro, Alexander R.: Board of Directors: AO Spine (Knowledge Forum Director), Flagship Surgical (None),  Innovative Surgical Design (None), Parvizi Surgical Innovation (Nonfinancial), Prime Surgeons (Nonfinancial), Progressive Spinal Technologies (Nonfinancial), Spine Therapy Network Inc (Nonfinancial); Consulting: Atlas Spine (B), Depuy (None), Gerson Lehrman Group (None), Globus (C), Guidepoint Global (B), Innovative Surgical Design (None), Medtronics (B), Nuvasive (None), Orthobullets (None), Spine Wave (B), Stout Medical (None), Stryker Spine (F); Other: Clinical Spine Surgery (Editor in Chief); Royalties: Elsevier (B),  Globus (F), JayPee Books (A), Medtronic (E), Stryker Spine (F), Taylor Francis (A), Thieme (B); Stock Ownership (including options, warrants): Advanced Spinal Intellectual Properties (30%), Avaz Surgical (less than 1%), Bonovo Orthopaedics (less than 1%), Computational Biodynamics (less than 1%),  Cytonics (less than 1%), Dimension Orthotics LLC (less than 1%), Electrocore (D), Flagship Surgical (less than 1%), FlowPharma (less than 1%), Franklin Bioscience (less than 1%), Globus (111,098 shares), Innovative Surgical Design (less than 1%), Insight Therapeutics (less than 1%), Nuvasive (less than 1%),  Paradigm Spine (less than 1%), Parvizi Surgical Innovation (less than 1%), Prime Surgeons (less than 1%), Progressive Spinal Technology (less than 1%),  Replication Medica (less than 1%), Spine Medica (less than 1%), Spinology (less than 1%), Stout Medical (631 shares), Vertiflex (less than 1%).  Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Alexander R. Vaccaro, MD, PhD (Thomas Jefferson University), Rick C. Sasso, MD (Indiana Spine Group and Indiana University School of Medicine), Carlo Bellabarba, MD (University of Washington and Harborview Medical Center) and Christopher K. Kepler, MD, MBA (Thomas Jefferson University) discuss type II odontoid fractures. Disclosures: Bellabarba, Carlo: Nothing to Disclose   Kepler, Christopher K.: Grants: NIH (I, Paid directly to institution/employer); Other Office: Clinical Spine Surgery (Nonfinancial); Research Support (Staff and/or materials): CSRS (D, Paid directly to institution/employer), RTI (C, Paid directly to institution/employer); Royalties: Inion (None). Sasso, Rick C.: Board of Directors: Cervical Spine Research Society (None); Consulting: NuVasive (C); Research Support (Staff and/or materials): Cerapedics (E, Paid directly to institution/employer), Medtronic (B, Paid directly to institution/employer), Smith and Nephew (D, Paid directly to institution/employer); Royalties: Medtronic (I). Vaccaro, Alexander R.: Board of Directors: AO Spine (Knowledge Forum Director), Flagship Surgical (None),  Innovative Surgical Design (None), Parvizi Surgical Innovation (Nonfinancial), Prime Surgeons (Nonfinancial), Progressive Spinal Technologies (Nonfinancial), Spine Therapy Network Inc (Nonfinancial); Consulting: Atlas Spine (B), Depuy (None), Gerson Lehrman Group (None), Globus (C), Guidepoint Global (B), Innovative Surgical Design (None), Medtronics (B), Nuvasive (None), Orthobullets (None), Spine Wave (B), Stout Medical (None), Stryker Spine (F); Other: Clinical Spine Surgery (Editor in Chief); Royalties: Elsevier (B),  Globus (F), JayPee Books (A), Medtronic (E), Stryker Spine (F), Taylor Francis (A), Thieme (B); Stock Ownership (including options, warrants): Advanced Spinal Intellectual Properties (30%), Avaz Surgical (less than 1%), Bonovo Orthopaedics (less than 1%), Computational Biodynamics (less than 1%),  Cytonics (less than 1%), Dimension Orthotics LLC (less than 1%), Electrocore (D), Flagship Surgical (less than 1%), FlowPharma (less than 1%), Franklin Bioscience (less than 1%), Globus (111,098 shares), Innovative Surgical Design (less than 1%), Insight Therapeutics (less than 1%), Nuvasive (less than 1%),  Paradigm Spine (less than 1%), Parvizi Surgical Innovation (less than 1%), Prime Surgeons (less than 1%), Progressive Spinal Technology (less than 1%),  Replication Medica (less than 1%), Spine Medica (less than 1%), Spinology (less than 1%), Stout Medical (631 shares), Vertiflex (less than 1%). Key: A: $100-$1,000; B: $1001-$10,000; C: $10,001-$25,000; D: $25,001-$50,000; E: $50,001-$100,000; F: $100,001- $500,000; G: $500,001-$1M; H: $1,000,001- $2.5M; I: $2.5M+

Is Surgery Indicated for a Type II Odontoid Fracture?

The best podcast episodes on non-current politics. Covering topics such as universal basic income, democracy, poverty & justice and more. For anyone interested in learning more about politics that affect that world, not just now, but in the longer term. Add episodes you're interested into your queue below!

Best Non-Current Politics Podcasts

The best podcast episodes of anyone with an interesting story. With famous guests like Obama, LeBron James, Drake, Oprah Winfrey, Richard Branson, Michelle Obama, Serena Williams, to anyone who has a unique and interesting story to tell. Add episodes you're interested into your queue below!